ATDBio

Executive Summary

ATDBio, founded in 2007 and based in Southampton, UK, is a privately held company specializing in custom oligonucleotide synthesis for the genetics, genomics, synthetic biology, and diagnostics sectors. The company differentiates itself through a scientist-to-scientist approach, leveraging deep chemical expertise to deliver high-purity oligonucleotides with optimized yields. By focusing on advanced synthesis, purification, and analysis methods, ATDBio serves researchers and biotech firms requiring precision oligonucleotides for applications such as PCR, sequencing, gene synthesis, and diagnostic probes. While the company has not disclosed funding or valuation, its established presence in the competitive oligo market suggests a steady niche position. The growing demand for oligonucleotides in therapeutic areas like antisense and siRNA, as well as in synthetic biology, positions ATDBio for potential growth, though its private status limits visibility into financial performance and pipeline.

Upcoming Catalysts (preview)

• H2 2026Expansion into therapeutic oligonucleotide manufacturing60% success
• H1 2027Strategic partnership with a diagnostics company for customized probes50% success
• 2026Launch of a novel synthesis platform enabling high-throughput production45% success